{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:35:09Z","timestamp":1786995309398,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ophtha.2025.09.019","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:46:24Z","timestamp":1759218384000},"page":"187-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-5150","authenticated-orcid":false,"given":"Shani","family":"Pillar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-4039","authenticated-orcid":false,"given":"Akshay","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Hassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6778-7747","authenticated-orcid":false,"given":"Howard","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5461-8568","authenticated-orcid":false,"given":"Sapna","family":"Gangaputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-6342","authenticated-orcid":false,"given":"Laura J.","family":"Kopplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-0687","authenticated-orcid":false,"given":"Kelly","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-9594","authenticated-orcid":false,"given":"Kareem","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-5620","authenticated-orcid":false,"given":"Derek C.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6309-127X","authenticated-orcid":false,"given":"Keren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-5050","authenticated-orcid":false,"given":"Nicholas J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-9191","authenticated-orcid":false,"given":"Edmund","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.09.019_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2025.09.019_bib2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2025.09.019_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti\u2013tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.09.019_bib4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/keaa595","article-title":"Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis","volume":"60","author":"Maccora","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2025.09.019_bib5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjophthalmol-2018-312767","article-title":"Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study","volume":"105","author":"Sharma","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2025.09.019_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/09273948.2022.2152983","article-title":"Long-term experience with anti-tumor necrosis factor- \u03b1 therapy in the treatment of refractory, non-infectious intermediate, posterior, and panuveitis","volume":"32","author":"Corredores Dieb","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.09.019_bib7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","article-title":"Success of weekly adalimumab in refractory ocular inflammatory disease","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.09.019_bib8","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","article-title":"Escalation to weekly adalimumab for the treatment of ocular inflammation","volume":"29","author":"Liberman","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.09.019_bib9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.12940","article-title":"Adalimumab dose escalation is effective for managing secondary loss of response in Crohn\u2019s disease","volume":"40","author":"Ma","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2025.09.019_bib11","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1111\/jdv.18623","article-title":"Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes\u2014a retrospective single-centre review of real-world data","volume":"37","author":"Hussain","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41433-023-02800-9","article-title":"Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study","volume":"38","author":"\u00c7am","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2025.09.019_bib13","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/RHU.0000000000001707","article-title":"Weekly adalimumab, an effective alternative for refractory uveitis in children","volume":"28","author":"Roberts","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib14","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1080\/09273948.2023.2279682","article-title":"Effectiveness and safety of weekly adalimumab for non-infectious chronic anterior uveitis in children","volume":"31","author":"Huard","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.09.019_bib15","article-title":"Predictors of therapy success in weekly adalimumab for refractory uveitis: a retrospective cohort study","author":"Janetos","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2025.09.019_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/09273948.2025.2456637","article-title":"Real-world efficacy and safety of escalation to weekly adalimumab for chronic non-infectious uveitis: a multicenter study involving pediatric and adult patients","volume":"33","author":"Oklar","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2025.09.019_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","article-title":"Pharmacokinetics and concentration\u2013effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2025.09.019_bib20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2133.2012.11041.x","article-title":"Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study","volume":"167","author":"Leonardi","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2025.09.019_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apt.16479","article-title":"Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn\u2019s disease","volume":"54","author":"Mattoo","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2025.09.019_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ajo.2024.12.009","article-title":"High body mass index is associated with lower adalimumab serum levels and higher disease activity in noninfectious uveitis","volume":"271","author":"Pichi","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:23:24Z","timestamp":1775049804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025006062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0161642025006062"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.019","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Effectiveness of Escalating to Weekly Adalimumab Dosing for the Treatment of Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}